Showing results (311-320 of 618) with videos related to
Sort By:
Pageof 62
Neuro-Oncology|May 29, 2014
Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trialsMarc Chamberlain, Riccardo Soffietti, Jeffrey Raizer, et al.Cancer Research|August 17, 2019
Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in GlioblastomaXiaolong Li, Emmanuel Martinez-Ledesma, Chen Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS TumorsMrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, et al.Neuro-Oncology|August 19, 2024
Enhancing neuro-oncology care through equity-driven applications of artificial intelligenceMulki Mehari, Youssef Sibih, Abraham Dada, et al.Neuro-Oncology|September 12, 2023
Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current managementEdward K Avila, Steven Tobochnik, Sara K Inati, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.Neuro-Oncology|October 21, 2020
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymomaMark R Gilbert, Ying Yuan, Jimin Wu, et al.Nature Medicine|August 20, 2013
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapyKyrre E Emblem, Kim Mouridsen, Atle Bjornerud, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.Neuro-Oncology|March 6, 2024
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse gliomaIsabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern, et al.Pageof 62